Statistics

Total Visits

Views
Phase II Trial of Erlotinib plus Capecitabine as First-line Treatment for Metastatic Pancreatic Cancer (XELTA Study)130

Select a period of time:

Number of views in the range

Views
Phase II Trial of Erlotinib plus Capecitabine as First-line Treatment for Metastatic Pancreatic Cancer (XELTA Study)55

Views

Views
November 20254
December 202510
January 202610
February 20260
March 202616
April 20267
May 20268
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States25
Brazil4
United Kingdom3
Mexico3
Singapore3
Venezuela3
Germany3
Argentina2
Switzerland2
Colombia2
 

Top cities views

Views
Ashburn5
San Jose4
Frankfurt am Main3
Los Angeles2
Aiken1
Atlanta1
Beaumont1
Buenos Aires1
Ciudad Guayana1
Corrientes1